| Index | S&P 500 | P/E | 20.92 | EPS (ttm) | 2.93 | Insider Own | 0.65% | Shs Outstand | 190.16M | Perf Week | 0.26% |
| Market Cap | 11.66B | Forward P/E | 12.06 | EPS next Y | 5.08 | Insider Trans | 2.81% | Shs Float | 188.94M | Perf Month | 7.71% |
| Enterprise Value | 14.05B | PEG | 2.24 | EPS next Q | 1.07 | Short Float | 4.81% | Perf Quarter | -17.93% | ||
| Income | 571.00M | P/S | 2.75 | EPS this Y | 3.32% | Short Ratio | 2.75 | Perf Half Y | -0.36% | ||
| Sales | 4.24B | P/B | 1.40 | EPS next Y | 8.58% | ROA | 4.50% | Short Interest | 9.09M | Perf YTD | -25.21% |
| Book/sh | 43.80 | P/C | 75.21 | EPS next 5Y | 9.35% | ROE | 6.88% | 52W High | 89.83 -32.63% | Perf Year | -12.57% |
| Cash/sh | 0.82 | P/FCF | 17.19 | EPS past 3/5Y | -1.22% -17.22% | ROIC | 4.76% | 52W Low | 51.01 18.63% | Perf 3Y | -20.35% |
| Dividend Est. | — | EV/EBITDA | 15.44 | Sales past 3/5Y | 7.35% 10.98% | Gross Margin | 63.64% | Volatility | 2.58% 2.45% | Perf 5Y | -40.91% |
| Dividend TTM | — | EV/Sales | 3.32 | EPS Y/Y TTM | 44.33% | Oper. Margin | 12.85% | ATR (14) | 1.63 | Perf 10Y | 37.14% |
| Dividend Ex-Date | Jul 26, 2023 | Quick Ratio | 0.73 | Sales Y/Y TTM | 4.75% | Profit Margin | 13.46% | RSI (14) | 58.90 | Recom | 2.54 |
| Dividend Gr. 3/5Y | 0.00% 0.00% | Current Ratio | 1.22 | EPS Q/Q | 4.55% | SMA20 | 5.60% | Beta | 0.80 | Target Price | 65.11 |
| Payout | 0.00% | Debt/Eq | 0.31 | Sales Q/Q | 0.57% | SMA50 | 2.12% | Rel Volume | 0.70 | Prev Close | 61.30 |
| Employees | 15,000 | LT Debt/Eq | 0.23 | Earnings | Dec 03 | SMA200 | -10.89% | Avg Volume | 3.50M | Price | 60.51 |
| IPO Date | Jan 21, 1983 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.34% -2.93% | Net Debt/EBITDA | 2.63 | Volume | 2,436,184 | Change | -1.28% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-06-26 | Initiated | Barclays | Equal Weight | $98 → $60 |
| Sep-10-26 | Reiterated | Stifel Nicolaus | Buy | $95 → $70 |
| Sep-10-26 | Reiterated | Robert W. Baird | $98 → $61 | |
| Sep-10-26 | Downgrade | Baird | Outperform → Neutral | |
| Sep-10-26 | Reiterated | Needham | Buy | $86 → $73 |
| Sep-10-26 | Downgrade | B of A Securities | Buy → Neutral | |
| Sep-10-26 | Downgrade | Piper Sandler | Overweight → Neutral | $86 → $59 |
| Sep-10-26 | Reiterated | UBS | Neutral | $66 |
| Sep-10-26 | Downgrade | William Blair | Outperform → Market Perform | |
| Sep-10-26 | Reiterated | Wells Fargo | Equal Weight | $66 → $61 |
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 10/31/2025 | FY 2024 10/31/2024 | FY 2023 10/31/2023 | FY 2022 10/31/2022 | FY 2021 10/31/2021 | FY 2020 10/31/2020 | FY 2019 10/31/2019 | FY 2018 10/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,237 | 4,092 | 3,895 | 3,593 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,540 | 1,610 | 1,300 | 1,235 | — | — | — | — | — | |
| Gross Profit | 2,696 | 2,483 | 2,596 | 2,358 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,886 | 1,628 | 1,534 | 1,501 | — | — | — | — | — | |
| Research and Development | 170 | 172 | 155 | 137 | — | — | — | — | — | |
| Other Operating Expense | 96 | 0 | 201 | 187 | — | — | — | — | — | |
| Operating Income | 544 | 683 | 706 | 533 | — | — | — | — | — | |
| Interest Expense | 94 | 100 | 114 | 105 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 13 | -16 | -9 | -15 | — | — | — | — | — | |
| Net Income Before Taxes | 463 | 567 | 582 | 413 | — | — | — | — | — | |
| Income Taxes | -108 | 192 | 190 | 119 | — | — | — | — | — | |
| Consolidated Net Income | 571 | 375 | 392 | 294 | — | — | — | — | — | |
| Net Income From Continuing Operations | 571 | 375 | 392 | 294 | — | — | — | — | — | |
| Net Income | 571 | 375 | 392 | 294 | — | — | — | — | — | |
| EPS (Recurring) | 2.93 | 1.88 | 1.97 | 1.49 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.93 | 1.88 | 1.97 | 1.49 | — | — | — | — | — | |
| EPS (Diluted) | 2.93 | 1.87 | 1.96 | 1.48 | — | — | — | — | — | |
| EBITDA | 910 | 1,053 | 1,072 | 886 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 20.65 | 37.39 | 53.41 | 52.66 | — | — | — | — | — | |
| Price To Sales Ratio | 2.76 | 3.42 | 5.35 | 4.30 | — | — | — | — | — | |
| Gross Margin | 63.63 | 60.68 | 66.65 | 65.63 | — | — | — | — | — | |
| Operating Margin | 12.84 | 16.69 | 18.13 | 14.83 | — | — | — | — | — | |
| Net Margin | 13.48 | 9.16 | 10.06 | 8.18 | — | — | — | — | — | |
| Shares Outstanding | 193 | 200 | 199 | 198 | — | — | — | — | — | |
| Market Capitalization | 11,679 | 13,982 | 20,831 | 15,432 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kurzius Lawrence Erik | Director | Sep 16 '26 | Buy | 54.93 | 10,000 | 549,320 | 31,099 | Sep 17 |
| Kurzius Lawrence Erik | Director | Sep 14 '26 | Buy | 53.91 | 10,000 | 539,150 | 21,099 | Sep 15 |
| Rosebrough Walter M Jr | Director | Sep 14 '26 | Buy | 54.29 | 3,000 | 162,870 | 20,000 | Sep 15 |
| Rosebrough Walter M Jr | Director | Sep 11 '26 | Buy | 54.11 | 7,000 | 378,770 | 17,000 | Sep 15 |
| Keel Paul A | Director | Sep 11 '26 | Buy | 53.18 | 4,701 | 250,000 | 4,701 | Sep 15 |
| Rosebrough Walter M Jr | Director | Apr 01 '26 | Option Exercise | 0.00 | 832 | 0 | 832 | Apr 21 |
| MADDEN TERESA S | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 15,679 | Apr 06 |
| Lucchese Cynthia L | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 12,767 | Apr 06 |
| Kurzius Lawrence Erik | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 11,099 | Apr 06 |
| WEISS ROBERT S | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,654 | 0 | 292,599 | Apr 06 |
| Rivas Maria | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 3,322 | Apr 06 |
| Jay Colleen | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 39,907 | Apr 06 |
| Carbone Barbara | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,050 | 0 | 3,050 | Apr 06 |
| Jay Colleen | Director | Jan 12 '26 | Option Exercise | 39.40 | 7,064 | 278,322 | 36,585 | Jan 14 |
| McBride Daniel G | EVP & Chief Operating Officer | Jan 08 '26 | Option Exercise | 0.00 | 12,887 | 0 | 76,007 | Jan 12 |